Moreover, we found that the HGF/c-Met crosstalk, maybe directly or through co-receptor Nrp1 [56], is important for tumor angiogenesis, acting in concert with VEGF released by breast cancer cells, therefore the combination of c-Met inhibitors and anti-angiogenic drugs could lead to a simultaneous targeting of c-Met and VEGF receptor increasing the effectiveness of chemotherapy. The gene discussed is MET; the disease is neoplasm.